Show simple item record

dc.contributor.authorFranco Pérez, Fernando
dc.contributor.authorLavernia, Javier
dc.contributor.authorAguiar-Bujanda, David
dc.contributor.authorMiramón, José
dc.contributor.authorGumá, Josep
dc.contributor.authorÁlvarez, Rut
dc.contributor.authorGómez-Codina, José
dc.contributor.authorGarcía Arroyo, Francisco Ramón 
dc.contributor.authorLlanos, Marta
dc.contributor.authorMarin, Miguel
dc.contributor.authorAlfaro, Jesus
dc.contributor.authorQuero, Cristina
dc.contributor.authorDelgado, Mayte
dc.contributor.authorNogales, Esteban
dc.contributor.authorMenarguez, Francisco
dc.contributor.authorMartinez, Natividad
dc.contributor.authorTorrente, Maria
dc.contributor.authorRoyuela, Ana
dc.contributor.authorAbreu, Delvys
dc.contributor.authorProvencio, Mariano
dc.date.accessioned2017-11-24T13:10:32Z
dc.date.available2017-11-24T13:10:32Z
dc.date.issued2017-03
dc.identifier.otherhttps://www.ncbi.nlm.nih.gov/pubmed/27847267es
dc.identifier.urihttp://hdl.handle.net/20.500.11940/9947
dc.description.abstractPrimary breast lymphoma is a rare form of localized extranodal lymphoma, which affects the mammary glands unilaterally or bilaterally, and can also affect the regional lymph nodes. We reviewed 55 patients, with disease stages IE and IIE, diagnosed in 16 Spanish institutions between 1989 and 2016. A serial of clinical variables and treatment were collected, and overall survival (OS) and progression-free survival (PFS) were calculated. Of the 55 patients, 96.4% were women with an average age of 69 years. A total of 53 patients corresponded to non-Hodgkin lymphoma (NHL), of whom 36.3% had lymph node involvement upon diagnosis. Of the patients, 58.2% were stage IE, and 41.8% were stage IIE. Treatments received included radiotherapy (36.3%), chemotherapy (85.5%), and rituximab (in 38 of the 45 patients with NHL treated with chemotherapy). In all, 82.2% of complete responses were achieved. OS and progression-free survival at 5 years in NHL patients was 76% and 73%, respectively. Current treatments (chemotherapy, immunotherapy, and radiotherapy) achieve good control of the disease, with an OS of 5 years in 80% of the patients, although there is no consensus in treatment, given the scarce incidence of these lymphomas.es
dc.language.isoenges
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subject.meshImmunotherapy *
dc.subject.meshBreast *
dc.subject.meshBreast Neoplasms *
dc.subject.meshRadiotherapy *
dc.subject.meshLymphoma, Non-Hodgkin *
dc.subject.meshMedical Oncology *
dc.subject.meshLymphoma *
dc.titlePrimary Breast Lymphoma: Analysis of 55 Cases of the Spanish Lymphoma Oncology Groupes
dc.typeArtigoes
dc.rights.holderlos autoreses
dc.identifier.doi10.1016/j.clml.2016.09.004
dc.identifier.essn2152-2669
dc.identifier.pmid27847267
dc.issue.number3es
dc.journal.titleClinical lymphoma, myeloma & leukemiaes
dc.organizationServizo Galego de Saúde::Estrutura de Xestión Integrada (EOXI)::EOXI de Pontevedra e O Salnés - Complexo Hospitalario Universitario de Pontevedra::Oncoloxía médicaes
dc.page.initial186es
dc.page.final191es
dc.relation.publisherversionhttp://www.sciencedirect.com/science/article/pii/S2152265016305602?via%3Dihubes
dc.rights.accessRightsopenAccesses
dc.subject.decslinfoma *
dc.subject.decsinmunoterapia *
dc.subject.decsradioterapia *
dc.subject.decsneoplasias de la mama *
dc.subject.decsoncología médica *
dc.subject.decsmama *
dc.subject.decslinfoma no Hodgkin *
dc.subject.keywordQuimioterapiaes
dc.subject.keywordcancer de mamaes
dc.subject.keywordtumores de mamaes
dc.typefidesArtigo Científico (inclue Orixinal, Orixinal breve, Revisión Sistemática e Meta-análisis)es
dc.typesophosArtículo Originales
dc.volume.number17es


Files in this item

This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-NoDerivatives 4.0 Internacional
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-NoDerivatives 4.0 Internacional